Tamsulosin ups IFIS risk by more than 50%

Article

Tamsulosin increases the risk of intraoperative floppy iris syndrome (IFIS) during cataract surgery by more than 50%, according to results of a study published online ahead of print by Acta Ophthalmologica.

Tamsulosin increases the risk of intraoperative floppy iris syndrome (IFIS) during cataract surgery by more than 50%, according to results of a study published online ahead of print by Acta Ophthalmologica.

Ugur Keklikçi, MD of the Department of Ophthalmology in the Faculty of Medicine, Dicle University, Diyarbakir, Turkey and colleagues conducted a non-randomized, observational study of eyes (n=594) undergoing cataract surgery.

Of the 23 patients taking tamsulosin, 52% (n=12) displayed symptoms of IFIS: this accounted for 80% of all the eyes that developed IFIS (n=15). The odds ratio of IFIS development after tamsulosin use was 206.5; the risk ratio was 99.3. No other variable (age, duration of tamsulosin use etc) was found to influence the likelihood of IFIS development.

The researchers concluded that tamsulosin use significantly increases the likelihood of IFIS development, and that the duration of this usage is irrelevant.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.